The global Portal Hypertension Therapeutics market is expected to grow to $1.9B 2019

Tuesday 13 March 2012, Amsterdam

The industry analysis specialist, has released its new report, “Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Portal Hypertension Therapeutics market. The report identifies the key trends shaping and driving the global Portal Hypertension Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Portal Hypertension Therapeutics sector.


The Portal Hypertension Therapeutics Market is Forecast to Show Slow Growth

They estimated the global portal hypertension therapeutics market to be valued at $1.7 billion in 2011. It is expected to grow to $1.9 billion at a Compound Annual Growth Rate (CAGR) of 2.0% by 2019. This slow growth is due to the slow increase in the prevalent population, the domination of the market by generics and low likelihood of new product launches during the forecast period.


Current Treatment Options Create Significant Unmet Need in the Market

An analysis found that the unmet need in the portal hypertension market is significant, which implies that the market is not well served by the current treatment options. There are no drugs approved for the treatment of portal hypertension. The market is dominated by off-label generic drugs. Beta-blockers are the drugs mainly used for treatment of portal hypertension. However, due to contraindications and side effects beta-blocker therapy is discontinued in many patients. Therefore there is a need for novel drugs with better safety and efficacy profiles to capture the untapped market.


Weak Pipeline will have No Impact during the Forecast Period

An analysis showed that the portal hypertension therapeutics pipeline is weak with only three molecules in clinical development. There are no molecules in Phase III. There is one molecule in Phase II/III, but it is sponsored by an academic institution. The company sponsored molecules are in Phase II and are unlikely to have an impact on the market during the forecast period. Thus the portal hypertension market provides scope for new entrants with novel mechanisms of action aimed at the cause of the disease with better safety and efficacy profiles.